Population-Based Strategy for Preventing Diabetes and its Complications
DOI:
https://doi.org/10.17140/DROJ-4-e011Abstract
A recent report from the American College of Physicians (ACP) should cause a paradigm change for the treatment of diabetic
patients.1 The main purpose of diabetes therapy is the prevention of complications.2 The endpoint of many clinical trials is to lower
blood glucose levels, but intensive treatments aimed at lowering the HbA1c to less than 6.5% are often accompanied by hypoglycemia
as a side effect. At the same time, intensive regimens have not shown a reduction of cardiovascular complications in the longterm.
3-7 For example, the action to control cardiovascular risk in diabetes (ACCORD) trial was prematurely discontinued, following
the observation of an increase in overall mortality, cardiovascular- related deaths, and severe hypoglycemic events.3 The action in diabetes and vascular disease; preterAx and diamicroN-MR controlled evaluation (ADVANCE) study also failed to show a statistically
significant clinical benefit, while more adverse effects were seen among those who achieved a median HbA1c level of 6.4%.4 More intensive treatments with tight glycemic control targets are more costly and associated with increased patient burdens. Only
Hollan et al8 reported a long-term benefit with intensive therapy in the United Kingdom prospective diabetes study (UKPDS) after
10 years of intervention.
References
Americal College of Physicians. Clinical Guidelines and Recom-mendations. Web site. http://www.acponline.org/clinical-infor-mation/guidelines. Accessed March 18, 2017.
Ojo O. An overview of diabetes and its complications. Diabetes Res Open J. 2016; 2(2): e4-e6. doi: 10.17140/DROJ-2-e005
Gerstein HC, Miller ME, Genuth S, et al. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardio-vascular outcomes. N Engl J Med. 2011; 364: 818-828. doi: 10.1056/ NEJMoa1006524
Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collabora-tive Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560- 2572. doi: 10.1056/NEJMoa0802987
Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-139. doi: 10.1056/NEJ-Moa0808431
UK Prospective Diabetes Study (UKPDS) Group. Effect of in-tensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352-854. doi: 10.1016/S0140-6736(98)07037-8
Hayward RA, Reaven PD, Wiitala WL, et al. VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 372: 2197-2206. doi: 10.1056/ NEJMoa1414266
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589. doi: 10.1056/NEJMoa0806470
Bajaj H, Zinman B. Diabetes: Steno-2 — a small study with a big heart. Nat Rev Endocrinol. 2016; 12(12): 692-694. doi: 10.1038/ nrendo.2016.172
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Ped-ersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5): 383-393. doi: 10.1056/NEJMoa021778
Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mel-litus and microalbuminuria: 21 years follow-up on the Steno-2 ran-domised trial. [Abstract taken from Diabetes Care. 2017; 40(Suppl 1): S75-S87.] Diabetologia. 2016; 59(11): 2298-2307. doi: 10.1007/ s00125-016-4065-6.
American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2017; 40(Suppl 1): S75-S87. PMID: 27979896. doi: 10.2337/dc17-S012 Editorial | Volume 4 | Number 1| Watanabe S
Ueki K, Sasako T, Kato M, et al. Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): A mul-ticenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Res Care. 2016 Jan 25; 4(1): e000123. doi: 10.1136/bmj-drc-2015-000123
J-DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): An open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(12): 951-964. doi: 10.1016/ S2213-8587(17)30327-3
Diabetes Resource Guide Japan. Revision of stage classifica-tion for DKD. Web site. www://dm-rg.net/news/2014/01/014349. html. Accessed March 18, 2017.
Japan Preventive Association of Life-style related Disease. Number of hemodialysis patients. Web site. www.seikatsusyukan-byo.com/statistics/2016/009096.php. Accessed March 18, 2017.
Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018; doi: 10.1016/S2213-8587(18)30051-2
Watanabe S, Noburu M, Yasunari M, Ideura T. A cross-sec-tional study on the effects of long term very low protein diets in patients with chronic kidney disease: Surum and urine DEXA and amino acid profiles. Anti-Aging Med. 2010; 7(2): 7-13. doi: 10.3793/ jaam.7.7
Watanabe S. Low-protein diet for the prevention of renal failure. Proc Japan Acad Ser B. 2017; 93(1): 1-9. doi: 10.2183/pjab.93.001
Watanabe S, Hirakawa A, Nishijima C, et al. Food as medicine: The new concept of “medical rice”. Adv Food Technol Nutr Sci Open J. 2016; 2(2): 38-50. doi: 10.17140/AFTNSOJ-2-129
Goto A, Noda M, Inoue M, Goto M, Charvat H. Increasing number of people with diabetes in Japan: Is this trend real? Intern Med. 2016; 55: 1827-1830. doi: 10.2169/internalmedicine.55.6475
World Health Organization 2016. Global report on diabetes. ISBN 978 92 4 156525 7 (NLM classification WK 810).
Herman WH, Ma Y, Uwaifo G, et al; Diabetes Prevention Pro-gram Research Group. Differences in A1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007 30: 2453. doi: 10.2337/ dc06-2003
Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: A systematic review. Diabetes Care. 2007; 30: 744-752. doi: 10.2337/dc06-1842
Nakade M, Aiba N, Suda N, et al; SCOP Group. Behavioral change during weight loss program and one-year follow-up: Saku e3 Control Obesity Program (SCOP in Japan). Asia Pac J Clin Nutr. 2012; 21(1): 22-34.
Ismail-Beigi F, Moghissi E, Kosiborod M, Inzucchi SE. Shift-ing paradigms in the medical management of type 2 diabetes: Re-flections on recent cardiovascular outcome trials. J Gen Intern Med. 2017; 32: 1044-1051. doi: 10.1007/s11606-017-4061-7
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and American college of endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015; 21: 1-87. doi: 10.4158/EP15672.GL
The Management of Type 2 Diabetes Mellitus in Primary Care Work Group. VA/DoD clinical practice guideline for the manage-Submit your article to this journal | https://openventio.org/submit-manuscript/ e4 Watanabe S ment of type 2 diabetes mellitus in primary care. Version 5.0. April 2017. Web site. https://www.healthquality.va.gov/guidelines/ CD/diabetes/VADoDDMCPGFinal508.pdf. Accessed August 8, 2017.
Watanabe S, Mizuno S, Hirakawa A. Effects of brown rice on obesity: GENKI Study I (Cross sectional epidemiological study). J Obesity Metab Dis. (Under peer review process)
Watanabe S, Mizuno S, Takahashi M, Hirakawa A. Diabetes and obesity-from GENKI Study. Clin Funct Nutr. 2018; 10(2): 79-86.
Hirakawa A, Melby M, Watanabe S. Comprehensive Food La-beling for Obesity Control. Advances in Obesity, Weight Management & Control. 2016; 4(3): 00088. doi: 10.15406/aowmc.2016.04.00088
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
